Cwm LLC Raises Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

Cwm LLC increased its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) by 216.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,011 shares of the company’s stock after purchasing an additional 1,376 shares during the period. Cwm LLC’s holdings in Denali Therapeutics were worth $43,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in DNLI. Assetmark Inc. grew its holdings in Denali Therapeutics by 49.1% in the 3rd quarter. Assetmark Inc. now owns 2,148 shares of the company’s stock valued at $44,000 after buying an additional 707 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Denali Therapeutics by 96.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,526 shares of the company’s stock worth $73,000 after purchasing an additional 1,732 shares during the last quarter. Victory Capital Management Inc. raised its stake in Denali Therapeutics by 5.5% during the third quarter. Victory Capital Management Inc. now owns 12,081 shares of the company’s stock worth $249,000 after purchasing an additional 630 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Denali Therapeutics during the 3rd quarter valued at $356,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Denali Therapeutics during the 3rd quarter worth $359,000. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and set a $95.00 price target on shares of Denali Therapeutics in a research report on Wednesday. Wedbush cut their price target on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday. UBS Group dropped their price objective on shares of Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, April 9th. The Goldman Sachs Group reduced their target price on shares of Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, February 29th. Finally, Stifel Nicolaus lowered their price target on Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating for the company in a report on Wednesday. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Denali Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.22.

Denali Therapeutics Price Performance

Shares of Denali Therapeutics stock opened at $18.67 on Friday. Denali Therapeutics Inc. has a 1-year low of $14.56 and a 1-year high of $33.31. The business has a 50-day moving average of $18.77 and a 200-day moving average of $18.84. The company has a market capitalization of $2.66 billion, a PE ratio of -17.29 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.01. Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same quarter in the prior year, the firm posted ($0.80) EPS. On average, equities analysts expect that Denali Therapeutics Inc. will post -2.61 earnings per share for the current fiscal year.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $18.37, for a total transaction of $30,604.42. Following the completion of the transaction, the director now directly owns 121,375 shares of the company’s stock, valued at approximately $2,229,658.75. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Vicki L. Sato sold 1,666 shares of Denali Therapeutics stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $18.37, for a total value of $30,604.42. Following the completion of the transaction, the director now directly owns 121,375 shares in the company, valued at $2,229,658.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Ryan J. Watts sold 9,589 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total value of $165,793.81. Following the completion of the sale, the chief executive officer now directly owns 238,067 shares of the company’s stock, valued at $4,116,178.43. The disclosure for this sale can be found here. Insiders have sold 110,955 shares of company stock valued at $2,218,802 over the last ninety days. Corporate insiders own 7.90% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.